MHRA receives Yellow Card reports of viral rebound in people treated with Paxlovid

摘要

A "small number" of Yellow Card reports of people who have tested positive for COV1D-19 after completing treatment with the antiviral Paxlovid (nirmatrelvir and ritonavir; Pfizer) have been received by the Medicines and Healthcare products Regulatory Agency (MHRA). In a statement shared with The Pharmaceutical Journal on 12 May 2022, the MHRA said that the reports were in line with that seen in Paxlovid clinical trials, in which 1-2% of patients continued to test positive for COVID-19 after a course of treatment in both arms of the trial.